BRIEF published on 09/08/2026 at 22:05, 9 days 2 hours ago Inventiva presents its advancements at the Paris MASH 2026 Congress Inventiva MASH Lanifibranor Clinical Phase PPAR
BRIEF published on 09/08/2026 at 22:05, 9 days 2 hours ago Inventiva to Showcase Lanifibranor Data at Paris MASH 2026 Clinical Data Inventiva MASH Lanifibranor PPAR Agonist
PRESS RELEASE published on 09/08/2026 at 22:00, 9 days 2 hours ago Inventiva to Present Multiple Abstracts at Paris MASH 2026 Inventiva to present Phase 1 and Phase 2 clinical data on lanifibranor at Paris MASH 2026, showing improvements in metabolic and cardiovascular factors in MASH patients. Lanifibranor's pan-PPAR pharmacology highlighted Clinical Data Inventiva Lanifibranor Metabolic Dysfunction Paris MASH 2026
BRIEF published on 09/02/2026 at 22:10, 15 days 2 hours ago Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study Clinical Study Phase 3 Inventiva MASH Lanifibranor
BRIEF published on 09/02/2026 at 22:10, 15 days 2 hours ago Inventiva Completes Key Milestone in MASH Clinical Trial Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
PRESS RELEASE published on 09/02/2026 at 22:05, 15 days 2 hours ago Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Inventiva completes last patient visit in Phase 3 trial for lanifibranor in MASH treatment, with topline results expected in Q4 2026. Financial results update scheduled for H1 2026 Phase 3 Trial Inventiva Lanifibranor MASH Treatment Financial Results Update
BRIEF published on 08/31/2026 at 22:10, 17 days 2 hours ago Inventiva Appoints Chris Benecchi as Chief Operating Officer Biopharmaceutical Phase 3 Study Inventiva Lanifibranor Chris Benecchi
BRIEF published on 08/31/2026 at 22:10, 17 days 2 hours ago Chris Benecchi appointed COO by Inventiva Biopharmaceutical Inventiva MASH Lanifibranor Chris Benecchi
PRESS RELEASE published on 08/31/2026 at 22:05, 17 days 2 hours ago Inventiva Appoints Chris Benecchi as Chief Operating Officer Inventiva appoints Chris Benecchi as Chief Operating Officer to lead operational readiness for lanifibranor Phase 3 study results and potential commercialization, enhancing MASH treatment approach Chief Operating Officer Inventiva MASH Lanifibranor Chris Benecchi
BRIEF published on 07/29/2026 at 22:05, 1 month 19 days ago Inventiva Releases Preliminary Financial Results for H1 2026 Cash Flow Biopharmaceutical Inventiva R&D Expenses Financial Results 2026
Published on 09/17/2026 at 22:15, 1 hour 56 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 1 hour 56 minutes ago Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 2 hours 6 minutes ago Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value
Published on 09/17/2026 at 15:55, 8 hours 16 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 8 hours 46 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 19:00, 5 hours 11 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 5 hours 12 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 5 hours 46 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 6 hours 1 minute ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 6 hours 25 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 6 hours 31 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 6 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 17 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
